The emergence of clinical isolates capable of manufacturing extended spectrum beta lactamase (ESBL) has posed treatment problems. As a result, ESBLs are becoming a growing clinical problem around the world because they transmit resistance to broad range -lactam antibiotics. Because neonates are more susceptible to infections, infections are a serious issue in Neonatal Intensive Care Units (NICUs). When newborns are treated with cephalosporins, it causes therapeutic failure and neonatal mortality; thus, its detection and awareness of the current prevalence scenario are critical for infection control. The current investigation looked into the prevalence of ESBL producers among the infected neonates who were included in the study.
Materials and Procedures: During a 25-month investigation, 1611 suspected instances of newborn infections were included (December 2010 to January 2013). 211 of the 342 positive cases were determined to be gramme negative by rigorous microbiological standards and tested for the generation of ESBLs. The double disc diffusion test was used to suspect ESBL production, and the double disc synergy test (DDST) and the phenotypic confirmatory disc diffusion test were utilised to confirm it (PCDDT).
The results showed that 39.34% of the 212 isolates tested positive for ESBLs. DDST affirmed 29.39 percent, while PCDDT confirmed 27.97 percent. The most common ESBL producers discovered were Escherichia coli and K. pneumoniae. Finally, because of the high incidence of ESBL producers in N.I.C.Us, it is critical to detect ESBL production on a regular basis with sensitivity reports that can help neonatologists meet the therapeutic challenge.Author(S) Details
Manisha N. Shah
Department of Microbiology, Shree Ramakrishna Institute of Computer Education and Applied Sciences, Sarvajanik University, Surat, Gujarat, India.
View Book:- https://stm.bookpi.org/IMB-V2/article/view/4715
No comments:
Post a Comment